Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Feb;56(2):326-334.
doi: 10.1161/STROKEAHA.124.048496. Epub 2024 Dec 20.

Randomized Study Comparing First-Line Dual Versus Single-Stent Retriever Technique: TWIN2WIN

Affiliations
Randomized Controlled Trial

Randomized Study Comparing First-Line Dual Versus Single-Stent Retriever Technique: TWIN2WIN

Alejandro Tomasello et al. Stroke. 2025 Feb.

Erratum in

  • Correction to: Randomized Study Comparing First-Line Dual Versus Single-Stent Retriever Technique: TWIN2WIN.
    Tomasello A, Moreu M, Terceño M, Dinia L, Barrena Caballo MR, Requena M, Jablonska M, Cendrero J, Flores A, Ortega-Gutierrez S, Diana F, Henandez D, de Dios M, Rubiera M, Garcia-Tornel A, Rizzo F, Olivé M, Pérez-García C, Trejo Gallego C, Carmona T, Rodrigo-Gisbert M, Molina C, Ribo M. Tomasello A, et al. Stroke. 2025 Apr;56(4):e129. doi: 10.1161/STR.0000000000000489. Epub 2025 Mar 24. Stroke. 2025. PMID: 40127148 No abstract available.

Abstract

Background: The double-stent retriever (SR) technique has been described as an effective rescue technique when single-SR fails to induce recanalization. We aimed to assess the safety and efficacy of first-line double-SR in patients with stroke undergoing thrombectomy.

Methods: This was a multicenter, randomized, controlled, blinded adjudicated primary outcome study. Patients with a large vessel occlusion stroke within 24 hours after onset and undergoing thrombectomy were included. Upon confirmation of large vessel occlusion on initial angiogram, patients were randomly allocated to receive a first-line strategy: single-SR versus double-SR technique. Investigators could use their technique of choice if further passes were needed. The primary objective was to evaluate the efficacy of double-SR defined as first-pass complete recanalization (expanded Treatment in Cerebral Infarction grade 2c-3) compared with single-SR. First-pass recanalization and final successful recanalization (expanded Treatment in Cerebral Infarction grade 2b50-3) were centrally assessed by a blinded investigator. The safety outcome was the occurrence of a symptomatic intracerebral hemorrhage. The data safety monitoring board stopped the recruitment after a preplanned interim analysis because a predefined efficacy boundary was reached.

Results: From April 2022 to October 2023, 108 patients were included: 50 (46%) in the single-SR group and 58 (54%) in the double-SR group. First-pass recanalization was achieved in 12 of 50 patients (24%) allocated to single-SR and 27 of 58 patients (46%) allocated to double-SR (adjusted odds ratio, 2.72 [95% CI, 1.19-6.46]). Substantial reperfusion within 3 attempts was obtained in 42 patients (84%) allocated to single-SR and in 52 patients (89%) allocated to double-SR (adjusted odds ratio, 1.74 [95% CI, 0.5-5.76]). The mean number of passes was 2±1.3 with single-SR and 1.7±1 with double-SR (mean difference, -0.37 [95% CI, -0.9 to 0.06]). A symptomatic intracerebral hemorrhage occurred in 3 patients (6%) allocated to single-SR and in 6 patients (10%) allocated to double-SR (adjusted odds ratio, 1.66 [95% CI, 0.40-8.35]).

Conclusions: In patients with stroke undergoing thrombectomy, first-line double-SR is safe and superior to single-SR in achieving first-pass recanalization but not final recanalization. Implications on clinical outcomes should be studied in specifically designed trials.

Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05632458.

Keywords: reperfusion; stents; stroke; thrombectomy.

PubMed Disclaimer

Conflict of interest statement

Dr Ribo is the co-founder of Anaconda Biomed and Nora and has a consulting agreement with Medtronic, Cerenovus, Methinks, Vesalio, Stryker, Philips, Rapid Pulse, Sensome, and Apta Targets. Dr Tomasello reports consulting agreements with Anaconda Biomed, Balt, i-vascular, Medtronic, Perflow, and Stryker. Dr Moreu reports consulting agreements with Angionautix, Balt, Inspire Medical, Medtronic, and Stryker. Dr Ortega is an employee of Carver College of Medicine, University of Iowa; reports consulting agreements with Medtronic, Methinks, and MicroVention; and received grants from the National Institutes of Health, Siemens, and Stryker. The other authors report no conflicts.

References

Publication types

Associated data